Home > Publications Database > Outcome-associated factors in a molecularly defined cohort of central neurocytoma. > print

001     279157
005     20250713001400.0
024 7 _ |a 10.1007/s00401-025-02894-3
|2 doi
024 7 _ |a pmid:40498174
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:178058823
|2 altmetric
037 _ _ |a DZNE-2025-00685
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Krech, Maja
|b 0
245 _ _ |a Outcome-associated factors in a molecularly defined cohort of central neurocytoma.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1751963705_3177
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Central neurocytomas (CN) are intraventricular brain tumors predominantly occurring in young adults. Although prognosis is usually favorable, tumor recurrence is common, particularly following subtotal resection (STR). Currently, the risk of progression is evaluated using atypical features and an elevated Ki67 proliferation index. However, these markers lack consistent definitions, raising the need for objective criteria. Genome-wide DNA methylation profiles were examined in 136 tumors histologically classified as CN. Clinical/histopathological characteristics were assessed in 93/90 cases, and whole-exome sequencing was conducted in 12 cases. Clinical and molecular characteristics were integrated into a survival model to predict progression-free survival (PFS). A diagnosis of CN was epigenetically confirmed in 125 of 136 cases (92%). No DNA methylation subgroups were identified, but global DNA hypomethylation emerged as a hallmark feature of CN associated with higher recurrence risk. Risk stratification based on histological features of atypia and Ki67 proliferation index was not reproducible across neuropathologists. Hypomethylation at the FGFR3 locus, accompanied by increased FGFR3 protein expression, was observed in 97% of cases. Gross total resection was associated with significantly improved PFS compared to STR, while patients undergoing STR receiving radiotherapy had a better outcome (p = 0.0001). Younger patients were identified as having a higher risk of recurrence (p = 0.026). Patient age and treatment strategy were key factors associated with survival outcomes in this cohort. These findings underscore the importance of closer follow-up for younger patients and radiotherapy for STR cases. Furthermore, FGFR3 represents a hallmark feature and potential therapeutic target, warranting further investigation.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a DNA methylation profiling
|2 Other
650 _ 7 |a FGFR3
|2 Other
650 _ 7 |a Neurocytoma
|2 Other
650 _ 7 |a Progression-free survival
|2 Other
650 _ 7 |a Radiotherapy
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Neurocytoma: genetics
|2 MeSH
650 _ 2 |a Neurocytoma: pathology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Brain Neoplasms: genetics
|2 MeSH
650 _ 2 |a Brain Neoplasms: pathology
|2 MeSH
650 _ 2 |a DNA Methylation
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Neoplasm Recurrence, Local: genetics
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
700 1 _ |a Muench, Amos
|b 1
700 1 _ |a Teichmann, Daniel
|b 2
700 1 _ |a Kuzman, Peter
|b 3
700 1 _ |a Suwala, Abigail K
|b 4
700 1 _ |a Ippen, Franziska M
|b 5
700 1 _ |a Müther, Michael
|b 6
700 1 _ |a Weber, Katharina J
|b 7
700 1 _ |a Wenger-Alakmeh, Katharina
|b 8
700 1 _ |a Onken, Julia
|b 9
700 1 _ |a Vajkoczy, Peter
|b 10
700 1 _ |a Behling, Felix
|b 11
700 1 _ |a May, Sven-Axel
|b 12
700 1 _ |a Ntoulias, Georgios
|b 13
700 1 _ |a Krauss, Joachim K
|b 14
700 1 _ |a Atallah, Oday
|b 15
700 1 _ |a Esmaeilzadeh, Majid
|b 16
700 1 _ |a Mueller, Wolf C
|b 17
700 1 _ |a Heppner, Frank L
|0 P:(DE-2719)2812386
|b 18
|u dzne
700 1 _ |a Radbruch, Helena
|b 19
700 1 _ |a Dittmayer, Carsten
|b 20
700 1 _ |a Stenzel, Werner
|b 21
700 1 _ |a Koch, Arend
|b 22
700 1 _ |a Capper, David
|b 23
700 1 _ |a Kaul, David
|b 24
700 1 _ |a Paulus, Werner
|b 25
700 1 _ |a Plate, Karl H
|b 26
700 1 _ |a Steinbach, Joachim P
|b 27
700 1 _ |a Czabanka, Markus
|b 28
700 1 _ |a Beschorner, Rudi
|b 29
700 1 _ |a von Deimling, Andreas
|b 30
700 1 _ |a Bockmayr, Michael
|b 31
700 1 _ |a Neumann, Julia E
|b 32
700 1 _ |a Brandner, Sebastian
|b 33
700 1 _ |a Krieger, Teresa
|b 34
700 1 _ |a Hartmann, Christian
|b 35
700 1 _ |a Thomas, Christian
|b 36
700 1 _ |a Schweizer, Leonille
|b 37
773 _ _ |a 10.1007/s00401-025-02894-3
|g Vol. 149, no. 1, p. 61
|0 PERI:(DE-600)1458410-4
|n 1
|p 61
|t Acta neuropathologica
|v 149
|y 2025
|x 0001-6322
856 4 _ |u https://pub.dzne.de/record/279157/files/DZNE-2025-00685%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/279157/files/DZNE-2025-00685.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/279157/files/DZNE-2025-00685.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:279157
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2812386
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1810007
|k AG Heppner
|l Neuroimmunology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1810007
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21